(Total Views: 547)
Posted On: 11/24/2021 9:00:56 AM
Post# of 157634
Nope I would just rather talk about stuff like this.
“Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec”
“Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec”
(3)
(0)
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
